- Home
- FFNW vs MGNX Comparison
FFNW vs MGNX Comparison
Compare FFNW & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FFNW
- MGNX
- Stock Information
- Founded
- FFNW 1923
- MGNX 2000
- Country
- FFNW United States
- MGNX United States
- Employees
- FFNW N/A
- MGNX N/A
- Industry
- FFNW Banks
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- FFNW Finance
- MGNX Health Care
- Exchange
- FFNW Nasdaq
- MGNX Nasdaq
- Market Cap
- FFNW 197.8M
- MGNX 151.9M
- IPO Year
- FFNW N/A
- MGNX 2013
- Fundamental
- Price
- FFNW $22.64
- MGNX $2.20
- Analyst Decision
- FFNW Hold
- MGNX Hold
- Analyst Count
- FFNW 2
- MGNX 10
- Target Price
- FFNW $22.75
- MGNX $7.17
- AVG Volume (30 Days)
- FFNW 37.3K
- MGNX 551.0K
- Earning Date
- FFNW 04-29-2025
- MGNX 05-08-2025
- Dividend Yield
- FFNW 0.57%
- MGNX N/A
- EPS Growth
- FFNW N/A
- MGNX N/A
- EPS
- FFNW 0.12
- MGNX N/A
- Revenue
- FFNW $37,609,000.00
- MGNX $141,329,000.00
- Revenue This Year
- FFNW N/A
- MGNX $177.84
- Revenue Next Year
- FFNW $0.82
- MGNX N/A
- P/E Ratio
- FFNW $194.00
- MGNX N/A
- Revenue Growth
- FFNW N/A
- MGNX 16.68
- 52 Week Low
- FFNW $18.03
- MGNX $2.15
- 52 Week High
- FFNW $23.50
- MGNX $19.54
- Technical
- Relative Strength Index (RSI)
- FFNW 67.55
- MGNX 35.93
- Support Level
- FFNW $19.14
- MGNX $2.16
- Resistance Level
- FFNW $21.66
- MGNX $2.49
- Average True Range (ATR)
- FFNW 0.54
- MGNX 0.17
- MACD
- FFNW 0.02
- MGNX -0.00
- Stochastic Oscillator
- FFNW 97.67
- MGNX 7.87
About FFNW First Financial Northwest Inc.
First Financial Northwest Inc is the holding company. The Bank's business consists predominantly of attracting deposits from the general public, combined with borrowing from the FHLB of Des Moines and raising funds in the wholesale market then utilizing these funds to originate one-to-four family residential, multifamily, commercial real estate, construction/land, business, and consumer loans. The Bank's strategic initiatives seek to diversify its loan portfolio and broaden growth opportunities with its current risk tolerance levels and asset/liability objectives.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).